Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Because FGFR2 is a known oncogene in other cancers, several inhibitors are already used in the clinic today. When Tonelli and her colleagues inhibited FGFR2 at precisely the right moment ...

Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often ...

However, prostate cancer eventually becomes resistant to the inhibitors, which leads to a form of disease ... in Prostate Cancer”), which was published in December 2024 by Oncogene, placed particular ...

With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027. “We made important strides in 2024 as we ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...